(CVS) CVS Health - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1266501006
Stock: Insurance, Pharmacy, Retail
Total Rating 45
Risk 67
Buy Signal 0.58
| Risk 5d forecast | |
|---|---|
| Volatility | 35.8% |
| Relative Tail Risk | -9.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.85 |
| Alpha | 17.79 |
| Character TTM | |
|---|---|
| Beta | 0.448 |
| Beta Downside | 0.505 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.98% |
| CAGR/Max DD | 0.09 |
EPS (Earnings per Share)
Revenue
Description: CVS CVS Health March 04, 2026
CVS Health Corporation provides health solutions across three segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.
The Health Care Benefits segment offers various health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans. This segment serves a broad client base, including employers, individuals, and government entities. The health insurance sector is characterized by complex regulatory frameworks and significant competition.
The Health Services segment focuses on pharmacy benefit management (PBM) solutions. These services encompass plan design, formulary management, and specialty pharmacy services. PBMs play a crucial role in managing drug costs for health plans and employers.
The Pharmacy & Consumer Wellness segment operates retail pharmacies, selling prescription and over-the-counter drugs, as well as general merchandise. This segment also includes online retail pharmacy operations and specialty pharmacy services. Retail pharmacy chains are a key component of the healthcare delivery system, providing direct access to medication and health products.
To gain further insights into CVSs financial performance and market position, consider exploring its detailed financials and analyst ratings on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: 1.77b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.49 > 1.0 |
| NWC/Revenue: -3.48% < 20% (prev -4.28%; Δ 0.81% < -1%) |
| CFO/TA 0.04 > 3% & CFO 10.64b > Net Income 1.77b |
| Net Debt (85.08b) to EBITDA (9.86b): 8.63 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.28b) vs 12m ago 1.27% < -2% |
| Gross Margin: 13.77% > 18% (prev 0.14%; Δ 1363 % > 0.5%) |
| Asset Turnover: 156.4% > 50% (prev 147.2%; Δ 9.13% > 0%) |
| Interest Coverage Ratio: 1.68 > 6 (EBITDA TTM 9.86b / Interest Expense TTM 3.12b) |
Altman Z'' 0.90
| A: -0.05 (Total Current Assets 74.71b - Total Current Liabilities 88.69b) / Total Assets 261.06b |
| B: 0.23 (Retained Earnings 61.20b / Total Assets 261.06b) |
| C: 0.02 (EBIT TTM 5.25b / Avg Total Assets 257.14b) |
| D: 0.33 (Book Value of Equity 61.62b / Total Liabilities 185.68b) |
| Altman-Z'' Score: 0.90 = B |
Beneish M -3.00
| DSRI: 1.01 (Receivables 39.78b/36.47b, Revenue 402.07b/372.81b) |
| GMI: 1.00 (GM 13.77% / 13.79%) |
| AQI: 0.99 (AQ_t 0.61 / AQ_t-1 0.61) |
| SGI: 1.08 (Revenue 402.07b / 372.81b) |
| TATA: -0.03 (NI 1.77b - CFO 10.64b) / TA 261.06b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = AA |
What is the price of CVS shares?
As of March 04, 2026, the stock is trading at USD 80.49 with a total of 7,086,834 shares traded.
Over the past week, the price has changed by +8.51%, over one month by +4.76%, over three months by +8.20% and over the past year by +28.75%.
Over the past week, the price has changed by +8.51%, over one month by +4.76%, over three months by +8.20% and over the past year by +28.75%.
Is CVS a buy, sell or hold?
CVS Health has received a consensus analysts rating of 4.21.
Therefore, it is recommended to buy CVS.
- StrongBuy: 13
- Buy: 8
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96.5 | 19.9% |
| Analysts Target Price | 96.5 | 19.9% |
CVS Fundamental Data Overview March 01, 2026
P/E Trailing = 57.482
P/E Forward = 10.917
P/S = 0.2542
P/B = 1.3195
P/EG = 0.554
Revenue TTM = 402.07b USD
EBIT TTM = 5.25b USD
EBITDA TTM = 9.86b USD
Long Term Debt = 60.50b USD (from longTermDebt, last quarter)
Short Term Debt = 5.80b USD (from shortTermDebt, last quarter)
Debt = 93.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 85.08b USD (from netDebt column, last quarter)
Enterprise Value = 186.79b USD (101.65b + Debt 93.59b - CCE 8.45b)
Interest Coverage Ratio = 1.68 (Ebit TTM 5.25b / Interest Expense TTM 3.12b)
EV/FCF = 23.93x (Enterprise Value 186.79b / FCF TTM 7.81b)
FCF Yield = 4.18% (FCF TTM 7.81b / Enterprise Value 186.79b)
FCF Margin = 1.94% (FCF TTM 7.81b / Revenue TTM 402.07b)
Net Margin = 0.44% (Net Income TTM 1.77b / Revenue TTM 402.07b)
Gross Margin = 13.77% ((Revenue TTM 402.07b - Cost of Revenue TTM 346.70b) / Revenue TTM)
Gross Margin QoQ = 12.84% (prev 13.42%)
Tobins Q-Ratio = 0.72 (Enterprise Value 186.79b / Total Assets 261.06b)
Interest Expense / Debt = 0.84% (Interest Expense 787.0m / Debt 93.59b)
Taxrate = 19.10% (408.0m / 2.14b)
NOPAT = 4.25b (EBIT 5.25b * (1 - 19.10%))
Current Ratio = 0.84 (Total Current Assets 74.71b / Total Current Liabilities 88.69b)
Debt / Equity = 1.24 (Debt 93.59b / totalStockholderEquity, last quarter 75.21b)
Debt / EBITDA = 8.63 (Net Debt 85.08b / EBITDA 9.86b)
Debt / FCF = 10.90 (Net Debt 85.08b / FCF TTM 7.81b)
Total Stockholder Equity = 75.61b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.69% (Net Income 1.77b / Total Assets 261.06b)
RoE = 2.34% (Net Income TTM 1.77b / Total Stockholder Equity 75.61b)
RoCE = 3.86% (EBIT 5.25b / Capital Employed (Equity 75.61b + L.T.Debt 60.50b))
RoIC = 3.01% (NOPAT 4.25b / Invested Capital 141.01b)
WACC = 4.27% (E(101.65b)/V(195.24b) * Re(7.57%) + D(93.59b)/V(195.24b) * Rd(0.84%) * (1-Tc(0.19)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.74%
[DCF] Terminal Value 83.64% ; FCFF base≈7.21b ; Y1≈5.71b ; Y5≈3.79b
[DCF] Fair Price = 24.91 (EV 116.78b - Net Debt 85.08b = Equity 31.70b / Shares 1.27b; r=5.90% [WACC]; 5y FCF grow -24.86% → 2.90% )
EPS Correlation: -57.92 | EPS CAGR: -17.28% | SUE: 0.27 | # QB: 0
Revenue Correlation: 96.82 | Revenue CAGR: 8.88% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.83 | Chg7d=+0.000 | Chg30d=-0.065 | Revisions Net=-10 | Analysts=21
EPS current Year (2026-12-31): EPS=7.17 | Chg7d=+0.000 | Chg30d=-0.002 | Revisions Net=-2 | Growth EPS=+6.2% | Growth Revenue=+1.1%
EPS next Year (2027-12-31): EPS=8.18 | Chg7d=-0.001 | Chg30d=-0.029 | Revisions Net=+3 | Growth EPS=+14.2% | Growth Revenue=+4.8%
[Analyst] Revisions Ratio: -0.71 (2 Up / 12 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.2% (Discount Rate 7.9% - Earnings Yield 1.7%)
[Growth] Growth Spread = -5.1% (Analyst 1.1% - Implied 6.2%)
P/E Forward = 10.917
P/S = 0.2542
P/B = 1.3195
P/EG = 0.554
Revenue TTM = 402.07b USD
EBIT TTM = 5.25b USD
EBITDA TTM = 9.86b USD
Long Term Debt = 60.50b USD (from longTermDebt, last quarter)
Short Term Debt = 5.80b USD (from shortTermDebt, last quarter)
Debt = 93.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 85.08b USD (from netDebt column, last quarter)
Enterprise Value = 186.79b USD (101.65b + Debt 93.59b - CCE 8.45b)
Interest Coverage Ratio = 1.68 (Ebit TTM 5.25b / Interest Expense TTM 3.12b)
EV/FCF = 23.93x (Enterprise Value 186.79b / FCF TTM 7.81b)
FCF Yield = 4.18% (FCF TTM 7.81b / Enterprise Value 186.79b)
FCF Margin = 1.94% (FCF TTM 7.81b / Revenue TTM 402.07b)
Net Margin = 0.44% (Net Income TTM 1.77b / Revenue TTM 402.07b)
Gross Margin = 13.77% ((Revenue TTM 402.07b - Cost of Revenue TTM 346.70b) / Revenue TTM)
Gross Margin QoQ = 12.84% (prev 13.42%)
Tobins Q-Ratio = 0.72 (Enterprise Value 186.79b / Total Assets 261.06b)
Interest Expense / Debt = 0.84% (Interest Expense 787.0m / Debt 93.59b)
Taxrate = 19.10% (408.0m / 2.14b)
NOPAT = 4.25b (EBIT 5.25b * (1 - 19.10%))
Current Ratio = 0.84 (Total Current Assets 74.71b / Total Current Liabilities 88.69b)
Debt / Equity = 1.24 (Debt 93.59b / totalStockholderEquity, last quarter 75.21b)
Debt / EBITDA = 8.63 (Net Debt 85.08b / EBITDA 9.86b)
Debt / FCF = 10.90 (Net Debt 85.08b / FCF TTM 7.81b)
Total Stockholder Equity = 75.61b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.69% (Net Income 1.77b / Total Assets 261.06b)
RoE = 2.34% (Net Income TTM 1.77b / Total Stockholder Equity 75.61b)
RoCE = 3.86% (EBIT 5.25b / Capital Employed (Equity 75.61b + L.T.Debt 60.50b))
RoIC = 3.01% (NOPAT 4.25b / Invested Capital 141.01b)
WACC = 4.27% (E(101.65b)/V(195.24b) * Re(7.57%) + D(93.59b)/V(195.24b) * Rd(0.84%) * (1-Tc(0.19)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.74%
[DCF] Terminal Value 83.64% ; FCFF base≈7.21b ; Y1≈5.71b ; Y5≈3.79b
[DCF] Fair Price = 24.91 (EV 116.78b - Net Debt 85.08b = Equity 31.70b / Shares 1.27b; r=5.90% [WACC]; 5y FCF grow -24.86% → 2.90% )
EPS Correlation: -57.92 | EPS CAGR: -17.28% | SUE: 0.27 | # QB: 0
Revenue Correlation: 96.82 | Revenue CAGR: 8.88% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.83 | Chg7d=+0.000 | Chg30d=-0.065 | Revisions Net=-10 | Analysts=21
EPS current Year (2026-12-31): EPS=7.17 | Chg7d=+0.000 | Chg30d=-0.002 | Revisions Net=-2 | Growth EPS=+6.2% | Growth Revenue=+1.1%
EPS next Year (2027-12-31): EPS=8.18 | Chg7d=-0.001 | Chg30d=-0.029 | Revisions Net=+3 | Growth EPS=+14.2% | Growth Revenue=+4.8%
[Analyst] Revisions Ratio: -0.71 (2 Up / 12 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.2% (Discount Rate 7.9% - Earnings Yield 1.7%)
[Growth] Growth Spread = -5.1% (Analyst 1.1% - Implied 6.2%)